NV-387 Shows Promise Against Measles, Protects Lungs

NanoViricides, Inc. has announced that its lead drug, NV-387, demonstrates strong antiviral activity against the Measles virus. In cell culture studies and humanized animal models, NV-387 not only reduced viral presence but also protected the lungs, a critical factor in severe infections.

While no approved drugs currently exist for Measles, NV-387 has shown direct antiviral effects, improving cell survival in cytopathic effects assays. In animal models, NV-387 treatment extended survival from 7.4 to 17 days, a 130% increase. This is attributed to reduced lung damage and slowed disease progression.

NV-387 operates through a unique "Re-Infection Inhibition" mechanism, resembling structures used by viruses to attach to receptors. It is available as oral gummies, a convenient option for patients. With the spread of Measles, the need for antiviral treatments like NV-387 is becoming increasingly important.